RECRUITING

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Description

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Conditions

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Malignant Solid NeoplasmClonal Cytopenia of Undetermined SignificanceClonal HematopoiesisIdiopathic Cytopenia of Undetermined SignificanceNon-Neoplastic Hematopoietic and Lymphoid Cell DisorderOvarian CarcinomaMyeloid Neoplasm Post Cytotoxic Therapy
Talk to us

Related Conditions:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Malignant Solid NeoplasmClonal Cytopenia of Undetermined SignificanceClonal HematopoiesisIdiopathic Cytopenia of Undetermined SignificanceNon-Neoplastic Hematopoietic and Lymphoid Cell DisorderOvarian CarcinomaMyeloid Neoplasm Post Cytotoxic Therapy

Study Overview

On this page

Study Details

Study overview

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Condition
Recurrent Fallopian Tube Carcinoma
Intervention / Treatment

-

Contacts and Locations

Seattle

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
  • * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
  • * Subjects who have or have had a solid tumor diagnosis and any of the following:
  • * At least 4 months of exposure to a PARP inhibitor
  • * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm
  • * Individuals with a life expectancy of less than 6 months

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Washington,

Elizabeth Swisher, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

2031-12-31